TFS HealthScience Strengthens Partnership with Oncomatryx for OMTX705 Pancreatic Cancer Trials

In an exciting development in cancer research, TFS HealthScience, a reputable global Contract Research Organization (CRO), is enhancing its collaboration with Oncomatryx, an emerging biopharmaceutical company. This partnership is focused on the Phase Ib clinical trial evaluating OMTX705, an innovative antibody-drug conjugate (ADC) designed to target pancreatic cancer, specifically advanced or metastatic pancreatic adenocarcinoma.

Understanding the Collaboration

This trial, crucial for many warriors battling one of the most severe forms of cancer, will be conducted across clinical sites in Spain and the United States. This initiative springs from a shared mission to find effective solutions for a disease known for its grim statistics. The World Cancer Research Foundation highlights pancreatic cancer as one of the leading causes of cancer death globally, with over 510,000 new cases each year. The lack of effective therapies, showcased by a dismal five-year survival rate remaining below ten percent, signals an urgent need for new treatments.

The Significance of OMTX705

OMTX705 employs a distinct mechanism as an anti-fibroblast activation protein (FAP) ADC, targeting the tumor microenvironment and aiming to enhance therapeutic effects significantly. This new trial builds on the previous successful Phase I study that explored OMTX705's capabilities, both as a standalone treatment and in conjunction with pembrolizumab, in patients with advanced solid tumors. Promising outcomes from the recent Phase I trial serve as a strong basis for this upcoming Phase Ib study.

Kris O’Brien, Vice President and Head of Oncology & Rare Diseases at TFS, emphasized their commitment in collaboration with Oncomatryx by stating, “Our ongoing partnership underscores a mutual dedication to hastening the journey toward innovative therapies for tough-to-treat cancers such as pancreatic adenocarcinoma.” This joint endeavor is not merely a trial phase but a beacon of hope for patients faced with limited options.

TFS HealthScience’s Expertise

With over 20 years of experience, TFS HealthScience plays a pivotal role in oncology research, guiding an array of clinical trials for solid tumors and rare cancers alike. Their robust operational framework is complemented by a rich repository of therapeutic insights and global outreach. The ongoing collaboration with Oncomatryx exemplifies TFS's mission to provide tailored clinical solutions that push forward promising scientific research.

Laureano Simón, CEO of Oncomatryx, hailed TFS as a vital partner: “We are entering an exhilarating phase in our clinical exploration of OMTX705. TFS stands out as a trusted partner whose expertise is crucial in bringing our scientific innovations closer to patients who desperately require new treatment choices.”

Fueling Future Developments

This collaborative venture is backed by strong financial resources, following a successful €25 million fundraising completed at the end of 2024. With the anticipation of Phase I clinical data set to be revealed at major oncology conferences in 2025, OMTX705 is drawing attention for its innovative approach in tackling hard-to-treat tumors like pancreatic adenocarcinoma.

Together, TFS HealthScience and Oncomatryx aim to pave the way for groundbreaking advancements in the treatment landscape for pancreatic cancer. Their shared vision of improving patient outcomes fuels their ongoing efforts and recalls the essence of scientific inquiry and partnership in addressing one of the toughest battles in healthcare. As the clinical trial commences, stakeholders across the medical community and patients alike await promising results that could transform the future of treatment for pancreatic cancer.

For more information on TFS HealthScience, visit TFS HealthScience.
For additional insights about Oncomatryx and their research initiatives, check Oncomatryx.